Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Up 11.2% Since Last Earnings Report: Can It Continue?

Healthy New Drug Sales And A Refreshed Pipeline Helping Lundbeck Set A Bottom

Amgen Inc: Taking Patent Dynamics Into Account

iShares Nasdaq Biotechnology ETF

Vertex Pharmaceuticals

Biotech stocks have joined the fourth quarter rally and could post strong gains in the coming months.

Biotech Stocks Awaken From Long Slumber

Novartis

Sanofi

Medicines

Regeneron Pharmaceuticals

Swiss drugmaker Novartis  is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co  as it challenges cardiovascular medicines from Amgen Inc , Sanofi  and Regeneron Pharmaceuticals.

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Bristol-Myers

These two dividend-paying pharma stocks are basically immune to the whims of the broader economy.

2 Stocks to Buy If You're Worried About a Recession

Amgen (AMGN) concludes the pending buyout of Celgene's psoriasis drug Otezla to acquire its worldwide rights. The company also hikes its overall 2019 view.

Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance

Amgen raised its full-year outlook Thursday after the biotech company wrapped its acquisition of psoriasis treatment Otezla in the wake of Bristol-Myers Squibb's takeover of Celgene.
The post Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy appeared first on Investor's Business Daily.

Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy

Amgen Inc. AMGN, +0.45% raised Thursday its 2019 profit and revenue guidance ranges, after the closing of the acquisition of the worldwide rights to the psoriasis treatment Otezla from Celgene Corp.

Amgen raises full-year guidance after closing $13.4 billion Otezla acquisition

Biogen

SunTrust initiated coverage on Biogen and Amgen on Tuesday, saying solid drug pipelines and growth opportunities in China will drive outperformance.

China seen as the next big growth area for biotechs Biogen and Amgen

Amgen's shares posted stellar gains last month. Can this blue chip biotech stock keep churning higher?

Why Amgen's Stock Soared in October

BeiGene

Folks who haven’t been paying attention to the absolutely huge potential happening in biotech stocks right now -- both in the U.S. and other parts of the world -- have been put on notice.

This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma

The biggest risk to Amgen stock comes from health reform that might limit the number of drugs insurers pay for, creating price competition.

2020 Election Could Hurt Amgen Stock’s Healthy Dividend

Galera Therapeutics And Amgen In Severe Oral Mucositis

Mirati Therapeutics

Both biotechs are developing revolutionary new cancer drugs, but which stock is better for your portfolio right now?

Better Buy: Mirati Therapeutics vs. Amgen

BeiGene stock rocketed late Thursday after the biotech company announced a collaboration deal that will have Amgen take a $2.7 billion stake in it. That represents 20.5% of BeiGene.

Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech — Here's Why

Under the all-cash deal, Amgen will pay BeiGene shareholders $174.85 per share, a 25% premium to BeiGene's closing price on the Nasdaq on Wednesday.

Amgen takes 20% stake in Chinese biotech BeiGene for $2.7 billion

Amgen Inc. AMGN, +1.12% said late Thursday it was buying a sizable stake in a Chinese cancer biotech treatment company to increase its sales presence in the country.

Amgen acquires one-fifth of Chinese biotech BeiGene

Amgen (AMGN) posts encouraging third-quarter 2019 results. It raises its previously issued sales guidance slightly while increasing the earnings range significantly.

Amgen (AMGN) Beats on Q3 Earnings, Ends Neuroscience R&D

After the closing bell on Tuesday, Amgen Inc. (NASDAQ:AMGN) issued its third-quarter results.

Amgen Reports Lower 3rd-Quarter Sales

Amgen Inc. (AMGN) CEO Bob Bradway on Q3 2019 Results - Earnings Call Transcript

Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.

Amgen posts higher biosimilar sales, ends neuroscience program

Amgen stock was flat late Tuesday, though Amgen earnings of $3.66 per share on $5.74 billion in sales beat Wall Street's expectations. The biotech company's stock is nearing a buy point.

Biotech Giant Amgen Beat Third-Quarter, 2019 Outlook Estimates

When Amgen Inc. (NASDAQ: AMGN) released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66 in earnings per share (EPS) and $5.7 billion in revenue.

Why Amgen Failed to Impress in Q3

Shares of Amgen Inc. AMGN, +1.94% rose less than 1% in the extended session Tuesday after the pharma company beat third-quarter adjusted profit and revenue expectations even as its sales fell due to more competition.

News for Amgen Stock (AMGN)